Novel Steroidal Inhibitors of Human Cytochrome P45017.alpha.-Hydroxylase-C17,20-lyase): Potential Agents for the Treatment of Prostatic Cancer
The DOI matches its Crossref record; 33 of the 33 references it cites were found in a registry or an index.
Abstract
Steroidal compounds having a 17-(3-pyridyl) substituent together with a 16,17-double bond have been synthesized, using a palladium-catalyzed cross-coupling reaction of a 17-enol triflate with diethyl(3-pyridyl)borane, which are potent inhibitors of human testicular 17 alpha-hydroxylase-C17,20-lyase. The requirement for these structural features is stringent: compounds having 2-pyridyl (9), 4-pyridyl (10), or 2-pyridylmethyl (11) substituents instead of the 3-pyridyl substituent were either poor inhibitors or noninhibitory. Reduction of the 16,17-double bond to give 17 beta-pyridyl derivatives diminished potency with 3-pyridyl substitution (3-->27; IC50 for lyase, 2.9-->23 nM) but increased it with a 4-pyridyl substituent present (10-->28; IC50 1 microM-->53 nM). In contrast, a variety of substitution patterns in rings A-C of the steroid skeleton afforded inhibitors having potencies similar to those most closely related structurally to the natural substrates pregnenolone and progesterone, respectively 17-(3-pyridyl)androsta-5,16-dien-3 beta-ol (3, Kiapp < 1 nM; IC50 for lyase, 2.9 nM) and 17-(3-pyridyl)androsta-4,16-dien-3-one (15; IC50 for lyase, 2.1 nM). Thus compounds having variously aromatic ring A (18), saturated rings A/B (21, 22), and oxygenated ring C (26) exhibited IC50 values for lyase (1.8-3.0 nM) falling within a 2-fold range. The most potent compounds are candidates for development as drugs for the treatment of hormone-dependent prostatic carcinoma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Abiraterone acetate, a prodrug of abiraterone, is a selective inhibitor of androgen biosynthesis that potently blocks cytochrome P450 c17 (CYP17), a critical enzyme in testosterone synthesis, thereby blocking androgen synthesis by the adrenal glands and testes and within the prostate tumor.”
From Abiraterone and Increased Survival in Metastatic Prostate Cancer (2011) · cites this paper as [11]
Citations
Cites
A Controlled Trial of Leuprolide with and without Flutamide in Prostatic Carcinoma
Crawford, E. D., Eisenberger, M. A., McLeod, D. G., Spaulding, J. T., Benson, R., Dorr, F. A., Blumenstein, B. A., Davis, M. A., & Goodman, P. J. (1989) · New England Journal of Medicine · doi:10.1056/nejm198908173210702 · Cited by 1,464
Stamey, T. A., Freiha, F. S., McNeal, J. E., Redwine, E. A., Whittemore, A. S., & Schmid, H.-P. (1993) · Cancer · doi:10.1002/1097-0142(19930201)71:3+<933::aid-cncr2820711408>3.0.co;2-l · Cited by 799
Palladium-catalyzed cross-coupling reaction of organoboron compounds with organic triflates
Ohe, T., Miyaura, N., & Suzuki, A. (1993) · The Journal of Organic Chemistry · doi:10.1021/jo00060a041 · Cited by 321
A method for the regiospecific synthesis of enol triflates by enolate trapping
Mc Murry, J. E., & Scott, W. J. (1983) · Tetrahedron Letters · doi:10.1016/s0040-4039(00)81581-6 · Cited by 285
THE MECHANISM OF ENZYME-INHIBITOR-SUBSTRATE REACTIONS
Goldstein, A. (1944) · Journal of General Physiology · doi:10.1085/jgp.27.6.529 · Cited by 181
KETOCONAZOLE THERAPY FOR ADVANCED PROSTATE CANCER
Trachtenberg, J., & Pont, A. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92909-x · Cited by 162
Steroid Hormones: A Practical Approach
(1989) · Tumori Journal · doi:10.1177/030089168907500230 · Cited by 100
Labrie, F., Belanger, A., Simard, J., Labrie, C., & Dupont, A. (1993) · Cancer · doi:10.1002/1097-0142(19930201)71:3+<1059::aid-cncr2820711426>3.0.co;2-6 · Cited by 94
Is there a case for P-450 inhibitors in cancer treatment?
Wauwe, J. P. V., & Janssen, P. A. J. (1989) · Journal of Medicinal Chemistry · doi:10.1021/jm00130a001 · Cited by 88
FORTI, G., SALERNO, R., MONETI, G., ZOPPI, S., FIORELLI, G., MARINONI, T., NATALI, A., COSTANTINI, A., SERIO, M., MARTINI, L., et al. (1989) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-68-2-461 · Cited by 83
Cited by
Abiraterone and Increased Survival in Metastatic Prostate Cancer
de Bono, J. S., Logothetis, C. J., Molina, A., Fizazi, K., North, S., Chu, L., Chi, K. N., Jones, R. J., Goodman, O. B., Saad, F., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1014618 · Cited by 4,407
“Cardiac disorder* 106 (13) 26 (3) 7 (1) 42 (11) 7 (2) 2 (<1)”
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
Ryan, C. J., Smith, M. R., de Bono, J. S., Molina, A., Logothetis, C. J., de Souza, P., Fizazi, K., Mainwaring, P., Piulats, J. M., Ng, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1209096 · Cited by 2,796
Attard, G., Reid, A. H. M., Yap, T. A., Raynaud, F., Dowsett, M., Settatree, S., Barrett, M., Parker, C., Martins, V., Folkerd, E., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.9749 · Cited by 903
Guengerich, F. P. (1995) · Cytochrome P450 · doi:10.1007/978-1-4757-2391-5_14 · Cited by 728
Attard, G., Reid, A. H. M., A'Hern, R., Parker, C., Oommen, N. B., Folkerd, E., Messiou, C., Molife, L. R., Maier, G., Thompson, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0642 · Cited by 605
Sartor, O., & de Bono, J. S. (2018) · New England Journal of Medicine · doi:10.1056/nejmra1701695 · Cited by 546
Phenotypic screening in cancer drug discovery — past, present and future
Moffat, J. G., Rudolph, J., & Bailey, D. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4366 · Cited by 507
The Concise Guide to PHARMACOLOGY 2013/14: Enzymes
Alexander, S. P. H., Benson, H. E., Faccenda, E., Pawson, A. J., Sharman, J. L., Spedding, M., Peters, J. A., Harmar, A. J., & Collaborators, C. (2013) · British Journal of Pharmacology · doi:10.1111/bph.12451 · Cited by 425
O'Donnell, A., Judson, I., Dowsett, M., Raynaud, F., Dearnaley, D., Mason, M., Harland, S., Robbins, A., Halbert, G., Nutley, B., et al. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601879 · Cited by 382
Self-citationMetalated Heterocycles and Their Applications in Synthetic Organic Chemistry
Chinchilla, R., Nájera, C., & Yus, M. (2004) · Chemical Reviews · doi:10.1021/cr020101a · Cited by 348
Rice, M. A., Malhotra, S. V., & Stoyanova, T. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00801 · Cited by 309
Attard, G., Reid, A. H. M., Auchus, R. J., Hughes, B. A., Cassidy, A. M., Thompson, E., Oommen, N. B., Folkerd, E., Dowsett, M., Arlt, W., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2189 · Cited by 282
Richards, J., Lim, A. C., Hay, C. W., Taylor, A. E., Wingate, A., Nowakowska, K., Pezaro, C., Carreira, S., Goodall, J., Arlt, W., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-3980 · Cited by 259
Castration-resistant Prostate Cancer: From New Pathophysiology to New Treatment Targets
Chi, K. N., Bjartell, A., Dearnaley, D., Saad, F., Schröder, F. H., Sternberg, C., Tombal, B., & Visakorpi, T. (2009) · European Urology · doi:10.1016/j.eururo.2009.06.027 · Cited by 253
Androgen Receptor Rediscovered: The New Biology and Targeting the Androgen Receptor Therapeutically
Ryan, C. J., & Tindall, D. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.2005 · Cited by 244
Current treatment strategies for advanced prostate cancer
Komura, K., Sweeney, C. J., Inamoto, T., Ibuki, N., Azuma, H., & Kantoff, P. W. (2018) · International Journal of Urology · doi:10.1111/iju.13512 · Cited by 239
Steroid 17-hydroxylase and 17,20-lyase deficiencies, genetic and pharmacologic
Auchus, R. J. (2017) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2016.02.002 · Cited by 229
Guengerich, F. P. (2007) · Cytochrome P450 · doi:10.1007/0-387-27447-2_10 · Cited by 220
Attard, G., Belldegrun, A. S., & De Bono, J. S. (2005) · BJU International · doi:10.1111/j.1464-410x.2005.05821.x · Cited by 207
Evolution of androgen receptor targeted therapy for advanced prostate cancer
Wong, Y. N. S., Ferraldeschi, R., Attard, G., & de Bono, J. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.72 · Cited by 197
Ferraldeschi, R., Welti, J., Luo, J., Attard, G., & de Bono, J. S. (2015) · Oncogene · doi:10.1038/onc.2014.115 · Cited by 192
New Strategies in Metastatic Prostate Cancer: Targeting the Androgen Receptor Signaling Pathway
Attard, G., Richards, J., & de Bono, J. S. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0567 · Cited by 183
Targeting Continued Androgen Receptor Signaling in Prostate Cancer
Massard, C., & Fizazi, K. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2815 · Cited by 178
CYP17 inhibitors—abiraterone, C17,20-lyase inhibitors and multi-targeting agents
Yin, L., & Hu, Q. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2013.274 · Cited by 172
Jarman, M., Barrie, S. E., & Llera, J. M. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm981017j · Cited by 151
Self-citationGuengerich, F. P. (2015) · Springer eBooks · doi:10.1007/978-3-319-12108-6_9 · Cited by 217
The changing therapeutic landscape of castration-resistant prostate cancer
Yap, T. A., Zivi, A., Omlin, A. G., & Bono, J. S. D. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.117 · Cited by 159
Gilep, A. A., Sushko, T. A., & Usanov, S. A. (2010) · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics · doi:10.1016/j.bbapap.2010.06.021 · Cited by 145
Castration-Resistant Prostate Cancer: From New Pathophysiology to New Treatment
Sridhar, S. S., Freedland, S. J., Gleave, M. E., Higano, C. S., Mulders, P., Parker, C. C., Sartor, O. A., & Fred Saad, C. (2013) · European Urology · doi:10.1016/j.eururo.2013.08.008 · Cited by 152
Crona, D. J., & Whang, Y. E. (2017) · Cancers · doi:10.3390/cancers9060067 · Cited by 160
Kaku, T., Hitaka, T., Ojida, A., Matsunaga, N., Adachi, M., Tanaka, T., Hara, T., Yamaoka, M., Kusaka, M., Okuda, T., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.08.066 · Cited by 127
A review of mechanistic studies on aromatase (CYP19) and 17α-hydroxylase-17,20-lyase (CYP17)
Akhtar, M., Wright, J. N., & Lee-Robichaud, P. (2010) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2010.11.003 · Cited by 131
Yamamoto, Y., Loriot, Y., Beraldi, E., Zhang, F., Wyatt, A. W., Nakouzi, N. A., Mo, F., Zhou, T., Kim, Y., Monia, B. P., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1108 · Cited by 123
Ang, J. E., Olmos, D., & Bono, J. S. D. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604904 · Cited by 128
Njar, V. C. O., Kato, K., Nnane, I. P., Grigoryev, D. N., Long, B. J., & Brodie, A. M. H. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm970568r · Cited by 120
Cancer wars: natural products strike back
Basmadjian, C., Zhao, Q., Bentouhami, E., Djehal, A., Nebigil, C. G., Johnson, R. A., Serova, M., Gramont, A. D. E., Faivre, S. J., Raymond, É., et al. (2014) · Frontiers in Chemistry · doi:10.3389/fchem.2014.00020 · Cited by 142
Steroid biosynthesis and prostate cancer
Sharifi, N., & Auchus, R. J. (2012) · Steroids · doi:10.1016/j.steroids.2012.03.015 · Cited by 116
Yamaoka, M., Hara, T., Hitaka, T., Kaku, T., Takeuchi, T., Takahashi, J., Asahi, S., Miki, H., Tasaka, A., & Kusaka, M. (2012) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2012.01.001 · Cited by 123
Synthetic approaches to the 2011 new drugs
Ding, H. X., Liu, K. K. ‐., Sakya, S. M., Flick, A. C., & O’Donnell, C. J. (2013) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2013.02.061 · Cited by 117
Ling, Y., Li, J.-S., Yang, L., Kato, K., Klus, G. T., & Brodie, A. M. H. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm970337k · Cited by 113
CYP17 inhibition as a hormonal strategy for prostate cancer
Reid, A. H. M., Attard, G., Barrie, E., & Bono, J. S. D. (2008) · Nature Clinical Practice Urology · doi:10.1038/ncpuro1237 · Cited by 119
Castration-Resistant Prostate Cancer: Mechanisms, Targets, and Treatment
Amaral, T. M. S., Macedo, D., Fernandes, I., & Costa, L. (2012) · Prostate Cancer · doi:10.1155/2012/327253 · Cited by 133
Targeting CYP17: established and novel approaches in prostate cancer
Yap, T. A., Carden, C. P., Attard, G., & Bono, J. S. D. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.06.004 · Cited by 115
Purushottamachar, P., Godbole, A. M., Gediya, L. K., Martin, M. S., Vasaitis, T. S., Kwegyir‐Afful, A. K., Ramalingam, S., Ateş‐Alagöz, Z., & Njar, V. C. O. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400048v · Cited by 115
Haidar, S., Ehmer, P. B., Barassin, S., Batzl‐Hartmann, C., & Hartmann, R. W. (2003) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(03)00070-0 · Cited by 103
Breast cancer: Current and future endocrine therapies
Palmieri, C., Patten, D. K., Januszewski, A. P., Zucchini, G., & Howell, S. J. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.08.001 · Cited by 112
Transition-Metal-Catalyzed Reactions in Steroid Synthesis
Skoda‐Földes, R., & Kollár, L. (2003) · Chemical Reviews · doi:10.1021/cr020075g · Cited by 101
Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency
Auchus, R. J., Buschur, E. O., Chang, A. Y., Hammer, G. D., Ramm, C., Madrigal, D., Wang, G., Gonzalez, M., Xu, X. S., Smit, J. W., et al. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1258 · Cited by 97
Li, R., Evaul, K., Sharma, K. K., Chang, K.-H., Yoshimoto, J., Liu, J., Auchus, R. J., & Sharifi, N. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0908 · Cited by 97
Wächter, G. A., Hartmann, R. W., Sergejew, T. F., Grün, G. L., & Ledergerber, D. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950377t · Cited by 97
Abiraterone acetate in the treatment of prostate cancer
Thakur, A., Roy, A., Ghosh, A., Chhabra, M., & Banerjee, S. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.02.067 · Cited by 112
Molecular Pathways: Inhibiting Steroid Biosynthesis in Prostate Cancer
Ferraldeschi, R., Sharifi, N., Auchus, R. J., & Attard, G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0931 · Cited by 93
Targeting Nuclear Receptors with PROTAC degraders
Flanagan, J. J., & Neklesa, T. K. (2019) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2019.110452 · Cited by 92
Steroidogenic cytochrome P450 17A1 structure and function
Burris‐Hiday, S. D., & Scott, E. E. (2021) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2021.111261 · Cited by 100
CYP17- and CYP11B-dependent steroid hydroxylases as drug development targets
Hakki, T., & Bernhardt, R. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.07.006 · Cited by 98
Androgen receptor profiling predicts prostate cancer outcome
Stelloo, S., Nevedomskaya, E., van der Poel, H. G., de Jong, J., van Leenders, G. J. L. H., Jenster, G. W., Wessels, L. F. A., Bergman, A. M., & Zwart, W. T. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201505424 · Cited by 100
The biosynthesis of steroids and triterpenoids
D. Brown, G. (1998) · Natural Product Reports · doi:10.1039/a815653y · Cited by 88
Wnt/Beta-Catenin Signaling and Prostate Cancer Therapy Resistance
Yeh, Y. A., Guo, Q., Connelly, Z. M., Cheng, S., Yang, S., Prieto‐Domínguez, N., & Yu, X. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-32656-2_16 · Cited by 99
Yamaoka, M., Hara, T., & Kusaka, M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0255 · Cited by 94
Hartmann, R. W., Hector, M., Haidar, S., Ehmer, P. B., Reichert, W., & Jose, J. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm001008m · Cited by 86
Crona, D. J., Milowsky, M., & Whang, Y. E. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.256 · Cited by 87
Clement, O. O., Freeman, C. M., Hartmann, R. W., Handratta, V. D., Vasaitis, T. S., Brodie, A. M. H., & Njar, V. C. O. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020576u · Cited by 83
Molecular probes for human cytochrome P450 enzymes: Recent progress and future perspectives
Wu, J., Guan, X., Dai, Z., He, R.-J., Ding, X., Yang, L., & Ge, G. (2020) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2020.213600 · Cited by 78
Bruno, R. D., Vasaitis, T. S., Gediya, L. K., Purushottamachar, P., Godbole, A. M., Ateş‐Alagöz, Z., Brodie, A. M. H., & Njar, V. C. O. (2011) · Steroids · doi:10.1016/j.steroids.2011.06.002 · Cited by 81
Minireview: Androgen Metabolism in Castration-Resistant Prostate Cancer
Sharifi, N. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1007 · Cited by 76
Hu, Q., Yin, L., Jagusch, C., Hille, U. E., & Hartmann, R. W. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100400a · Cited by 76
The role of ketoconazole in current prostate cancer care
Patel, V. G., Liaw, B. C.-H., & Oh, W. K. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0077-y · Cited by 79
Targeting 5α-reductase for prostate cancer prevention and treatment
Nacusi, L. P., & Tindall, D. J. (2011) · Nature Reviews Urology · doi:10.1038/nrurol.2011.67 · Cited by 84
Concise Enantiospecific Total Synthesis of Tubingensin A
Goetz, A. E., Silberstein, A. L., Corsello, M. A., & Garg, N. K. (2014) · Journal of the American Chemical Society · doi:10.1021/ja501142e · Cited by 70
Non-steroidal CYP17A1 Inhibitors: Discovery and Assessment
Wróbel, T. M., Jørgensen, F. S., Pandey, A. V., Grudzińska, A., Sharma, K., Yakubu, J., & Björkling, F. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00442 · Cited by 79
Hu, Q., Yin, L., & Hartmann, R. W. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm3004637 · Cited by 69
The role of adrenal derived androgens in castration resistant prostate cancer
Barnard, M., Mostaghel, E. A., Auchus, R. J., & Storbeck, K. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.105506 · Cited by 70
Lewis, D. F. V., & Lee-Robichaud, P. (1998) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(98)00032-6 · Cited by 68
Overview of the latest treatments for castration-resistant prostate cancer
Bishr, M., & Saad, F. (2013) · Nature Reviews Urology · doi:10.1038/nrurol.2013.137 · Cited by 73
Bruno, R. D., Gover, T. D., Burger, A. M., Brodie, A. M. H., & Njar, V. C. O. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0336 · Cited by 67
Michalak, M., Michalak, K., & Wicha, J. (2017) · Natural Product Reports · doi:10.1039/c6np00107f · Cited by 62
Iványi, Z., Szabó, N., Huber, J., Woelfling, J., Zupkó, I., Szécsi, M., Wittmann, T., & Schneider, G. (2012) · Steroids · doi:10.1016/j.steroids.2012.02.001 · Cited by 61
Abiraterone in Prostate Cancer: A New Angle to an Old Problem
Stein, M. N., Goodin, S., & DiPaola, R. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1805 · Cited by 61
Inhibition of CYP 17, a New Strategy for the Treatment of Prostate Cancer
Hartmann, R. W., Ehmer, P. B., Haidar, S., Hector, M., Jose, J., Klein, C. D. P., Seidel, S. B., Sergejew, T. F., Wachall, B. G., Wächter, G. A., et al. (2002) · Archiv der Pharmazie · doi:10.1002/1521-4184(200204)335:4<119::aid-ardp119>3.0.co;2-# · Cited by 65
Salvador, J. A. R., Pinto, R. M. A., & Silvestre, S. (2013) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.04.006 · Cited by 82
Hu, Q., Negri, M., Jahn‐Hoffmann, K., Zhuang, Y., Ölgen, S., Bartels, M., Müller‐Vieira, U., Lauterbach, T., & Hartmann, R. W. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.07.011 · Cited by 60
Wachall, B. G., Hector, M., Zhuang, Y., & Hartmann, R. W. (1999) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(99)00160-1 · Cited by 60
Gohlke, H., Gündisch, D., Schwarz, S., SEITZ, G., Tilotta, M. C., & Wegge, T. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010936y · Cited by 60
Hoy, S. M. (2013) · Drugs · doi:10.1007/s40265-013-0150-z · Cited by 65
Morris, M. J., Heller, G., Hillman, D. W., Bobek, O. J., Ryan, C. J., Antonarakis, E. S., Bryce, A. H., Hahn, O. M., Beltran, H., Armstrong, A. J., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02394 · Cited by 61
Chan, F. C. Y., Potter, G. A., Barrie, S. E., Haynes, B. P., Rowlands, M. G., Houghton, J., & Jarman, M. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950749y · Cited by 57
Self-citationMatsunaga, N., Kaku, T., Ojida, A., Tanaka, T., Hara, T., Yamaoka, M., Kusaka, M., & Tasaka, A. (2004) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.06.016 · Cited by 58
Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
Stein, M., Patel, N., Bershadskiy, A., Sokoloff, A., & Singer, E. A. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.129133 · Cited by 67
Hu, Q., Jagusch, C., Hille, U. E., Haupenthal, J., & Hartmann, R. W. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100317b · Cited by 55
Abiraterone and Novel Antiandrogens: Overcoming Castration Resistance in Prostate Cancer
Ferraldeschi, R., Pezaro, C. J., Karavasilis, V., & Bono, J. S. D. (2012) · Annual Review of Medicine · doi:10.1146/annurev-med-121211-091605 · Cited by 57
Inhibitors of Steroidal Cytochrome P450 Enzymes as Targets for Drug Development
Baston, E., & Leroux, F. R. (2007) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489207779561453 · Cited by 53
The 5α-androstanedione pathway to dihydrotestosterone in castration-resistant prostate cancer
Sharifi, N. (2012) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31823874a4 · Cited by 52
Hartmann, R. W., Hector, M., Wachall, B. G., Palusczak, A., Palzer, M., Hüch, V., & Veith, M. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm991070n · Cited by 52
Swami, U., Sinnott, J. A., Haaland, B. A., Sayegh, N., McFarland, T. R., Tripathi, N., Maughan, B. L., Rathi, N., Sirohi, D., Nussenzveig, R. H., et al. (2021) · Cancers · doi:10.3390/cancers13194951 · Cited by 59
Palladium-Catalysed Coupling Reactions
de Vries, J. G. (2012) · Topics in organometallic chemistry · doi:10.1007/3418_2012_32 · Cited by 50
Progress of molecular targeted therapies for prostate cancers
Fu, W., Madan, E., Yee, M., & Zhang, H. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.11.003 · Cited by 55
Palladium catalysed coupling reactions
Frost, C. G. (1991) · Elsevier eBooks · doi:10.1016/b978-044453347-0.50425-0 · Cited by 48
Recent Progress in Pharmaceutical Therapies for Castration-Resistant Prostate Cancer
Yin, L., Hu, Q., & Hartmann, R. W. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms140713958 · Cited by 49
Specificity of anti-prostate cancer CYP17A1 inhibitors on androgen biosynthesis
Udhane, S. S., Dick, B., Hu, Q., Hartmann, R. W., & Pandey, A. V. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.07.019 · Cited by 46
Petrunak, E. M., Rogers, S. A., Aubé, J., & Scott, E. E. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.117.075317 · Cited by 51
Metadata
- Authors
- Potter, G. A., Barrie, S. E., Jarman, M., & Rowlands, M. G.
- Affiliations
- Institute of Cancer Research (GB)
- ORCID
- Jarman, Michael
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 1995-06
- Volume
- 38
- Issue
- 13
- Pages
- 2463-2471
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W2027081726
- Cited by
- 379
- References
- 33
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 13 · 2023: 15 · 2022: 10 · 2021: 11 · 2020: 13 · 2019: 12 · 2018: 11 · 2017: 21 · 2016: 20 · 2015: 21 · 2014: 28 · 2013: 31 · 2012: 28
- FWCI
- 9.10
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Physical Sciences › Chemistry › Organic Chemistry › Heterocyclic Compound Synthesis and Bioactivity
- Physical Sciences › Chemistry › Organic Chemistry › Steroid Chemistry and Biochemistry
- Keywords
- CYP17 inhibitors, steroids, palladium-catalyzed cross-coupling, structure-activity relationship, steroid synthesis, prostate cancer, hormone-dependent prostate cancer, androstenedione, pregnenolone, progesterone
- MeSH terms
- Humans, Male, Magnetic Resonance Spectroscopy, Prostatic Neoplasms, Steroid 17-alpha-Hydroxylase, Steroids, Structure-Activity Relationship, Testis, Cytochrome P-450 Enzyme Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.